Table V.
Correlations between the EZH2/HDAC1/2 expression and the clinicopathological characteristics in NK/TCL.
| EZH2 expression | HDAC1 expression | HDAC2 expression | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristic | High | Low | P-value | High | Low | P-value | High | Low | P-value |
| Sex | |||||||||
| Male | 2 (33.3) | 4 (66.7) | 0.589 | 3 (50.0) | 3 (50.0) | 1.000 | 1 (16.7) | 5 (83.3) | 0.035a |
| Female | 5 (62.5) | 3 (37.5) | 5 (62.5) | 3 (37.5) | 7 (87.5) | 1 (12.5) | |||
| Age, years | |||||||||
| ≤60 | 6 (85.7) | 6 (14.3) | 1.000 | 6 (50.0) | 6 (50.0) | 0.115 | 7 (58.3) | 5 (41.7) | 0.826 |
| >60 | 1 (85.7) | 1 (14.3) | 2 (100.0) | 0 (00.0) | 1 (50.0) | 1 (50.0) | |||
| B-symptoms | |||||||||
| Present | 6 (60.0) | 4 (40.0) | 0.554 | 7 (70.0) | 3 (30.0) | 0.348 | 6 (60.0) | 4 (40.0) | 1.000 |
| Absent | 1 (25.0) | 3 (75.0) | 1 (25.0) | 3 (75.0) | 2 (50.0) | 2 (50.0) | |||
| Marrow involvement | |||||||||
| Present | 2 (66.7) | 1 (33.3) | 1.000 | 2 (66.7) | 1 (33.3) | 1.000 | 2 (66.7) | 1 (33.3) | 1.000 |
| Absent | 5 (45.5) | 6 (54.5) | 6 (54.5) | 5 (45.5) | 6 (54.5) | 5 (45.5) | |||
| Splenomegaly | |||||||||
| Present | 3 (50.0) | 3 (50.0) | 1.000 | 4 (66.7) | 2 (33.3) | 0.938 | 5 (83.3) | 1 (16.7) | 0.242 |
| Absent | 4 (50.0) | 4 (50.0) | 4 (50.0) | 4 (50.0) | 3 (37.5) | 5 (62.5) | |||
| Stage | |||||||||
| I–II | 2 (50.0) | 2 (50.0) | 1.000 | 2 (50.0) | 2 (50.0) | 1.000 | 1 (25.0) | 3 (75.0) | 0.348 |
| III–IV | 5 (50.0) | 5 (50.0) | 6 (60.0) | 4 (40.0) | 7 (70.0) | 3 (30.0) | |||
| IPI | |||||||||
| 0–2 | 4 (50.0) | 4 (50.0) | 1.000 | 5 (62.5) | 3 (37.5) | 1.000 | 3 (37.5) | 5 (62.5) | 0.242 |
| 3–5 | 3 (50.0) | 3 (50.0) | 3 (50.0) | 3 (50.0) | 5 (83.3) | 1 (16.7) | |||
| B2M | |||||||||
| >Upper limit of normal | 6 (66.7) | 3 (33.3) | 0.265 | 5 (55.6) | 4 (44.4) | 1.000 | 6 (66.7) | 3 (33.3) | 0.687 |
| Normal | 1 (20.0) | 4 (80.0) | 3 (60.0) | 2 (40.0) | 2 (40.0) | 3 (60.0) | |||
| LDH | |||||||||
| >Upper limit of normal | 6 (60.0) | 4 (40.0) | 0.554 | 5 (50.0) | 5 (50.0) | 0.798 | 7 (70.0) | 3 (30.0) | 0.348 |
| Normal | 1 (33.3) | 3 (66.7) | 3 (75.0) | 1 (25.0) | 1 (25.0) | 3 (75.0) | |||
| WBC | |||||||||
| >Upper limit of normal | 0 (100.0) | 3 (00.0) | 0.193 | 1 (33.3) | 2 (66.7) | 0.778 | 0 (00.0) | 3 (100.0) | 0.110 |
| Normal | 7 (63.7) | 4 (36.3) | 7 (63.6) | 4 (36.4) | 8 (72.7) | 3 (27.3) | |||
| Ki-67 | |||||||||
| ≥30% | 4 (36.4) | 7 (63.6) | 0.193 | 5 (45.5) | 6 (54.5) | 0.301 | 5 (45.5) | 6 (54.5) | 0.301 |
| <30% | 3 (100.0) | 0 (00.0) | 3 (100.0) | 0 (00.0) | 3 (100.0) | 0 (00.0) | |||
a
P<0.05. EZH2, enhancer of zeste homolog 2; HDAC, histone deacetylase; NK/TCL, natural killer/T cell lymphoma; IPI, international prognostic index; B2M, β2 microglobulin; LDH, lactate dehydrogenase; WBC, white blood count